Fifteen years ago, Omuro et al. reported that the incidence of the central nervous system as an initial failure site reached 33% in EGFR-TKI responders with advanced NSCLC regardless of disease control in the lungs [31]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.